The approval was based on data from 2 identical phase 3 studies, PSOARING 1 and PSOARING 2.
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F.
Researchers investigated the generalizability of a previous study finding that increased mean corpuscular volume complements clinical response in psoriatic arthritis.
Candidate biomarkers for disease progression in psoriasis have been identified, according to a review published online.
Treatment with brodalumab was well tolerated and produced high levels of skin clearance over 120 weeks in patients with moderate to severe plaque psoriasis, according to results of a post hoc analysis of phase 2 and 3 clinical trials of brodalumab published in the Journal of the European Academy of Dermatology and Venereology. To address…
Women with psoriasis have a significantly increased risk for ectopic pregnancy (EP), which is highest for those with moderate-to-severe psoriasis.
Clinicians develop and test a 10-item short version of the Patient Benefit Index Standard version (PBI-S) for use by patients with psoriasis.
The POETYK PSO-LTE trial evaluated deucravacitinib 6mg orally once daily in 1221 adults with moderate to severe plaque psoriasis.
Authors of a systematic review compared the efficacy and safety of systemic therapies in the treatment of manifestations of active psoriatic arthritis.
Researchers sought to recognize and describe the patients with psoriasis at both ends of the biologic agent treatment spectrum.